2023 Fiscal Year Final Research Report
Elucidation of Epigenetic Control mechanisms by amelogenin and challenge for refractory diseases
Project/Area Number |
21K16972
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 57030:Conservative dentistry-related
|
Research Institution | Kyushu University |
Principal Investigator |
|
Project Period (FY) |
2021-04-01 – 2024-03-31
|
Keywords | アメロジェニン / 免疫抑制 / 創傷治癒 |
Outline of Final Research Achievements |
Previous studies reported that amelogenin inhibits the expression of MHC class II with reduced antigen presentation. This study aimed to investigate the influernce of amelogenin on skin graft rejection among the mice with different haplotype antigens. Recombinant amelogenin (rM180) was applied to the skin from C57BL/6J mice, followed by the transplantation onto recipient sites of BALB/c mice. The median survival period of the grafts was extended by up to 6 days compared to a PBS control group, accompanied by a reduction in necrotic area. Histological analysis of skin tissues at day 7 after transplantation showed significantly decreased inflammatory cell infiltration and MHC II+ cells in test group, while massive immune cell infiltration was observed in the control group. These findings may also suggest potential use of amelogenin for the prevention of rejection after organ transplantation.
|
Free Research Field |
歯周病学
|
Academic Significance and Societal Importance of the Research Achievements |
元来歯のエナメル質の石灰化と成熟にのみ関与するはずのアメロジェニンが免疫抑制作用を有するという現象は、歯の発生時に特殊な免疫システムが作動している可能性を示唆するものであり、発生期の歯胚防御の分子機序を解明する研究の発端となるかもしれない。さらに、使用したアメロジェニンは組み換え蛋白質であり、プリオン等の未知の病原蛋白質を含まないため、生体に安全に使用できる。昨今の免疫抑制剤には重篤な副作用が認められるものが多数確認されており、将来的にアメロジェニンが臓器移植を始め、I型糖尿病、多発性硬化症、関節リウマチなどのMHC II関連自己免疫疾患に対する安全な免疫抑制剤として応用できる可能性がある。
|